How Hayat Pharmaceuticals Consulting Helps Biotech Startups

Building a biotech startup is one of the most ambitious things a scientist or entrepreneur can do. You have a molecule with potential. You have a vision for how it could change patients’ lives. But between that vision and a commercially approved drug lies one of the most complex regulatory processes in the world: FDA approval.

For most biotech startups, the FDA approval journey is unfamiliar territory. The pathways are complicated, the documentation requirements are enormous, and the cost of mistakes is measured in months of delay and millions of dollars. A single misstep in your Investigational New Drug (IND) application, a poorly designed bioequivalence study, or a gap-filled Chemistry, Manufacturing, and Controls (CMC) section can set your program back by years.

This is where Hayat Pharmaceuticals Consulting (HPC) comes in. HPC is a US-based pharmaceutical consulting firm founded by Dr. Umar Hayat, a scientist with a PhD in process engineering, decades of hands-on drug development experience, and a direct role in the commercialization of multiple FDA-approved products, including Veltassa®, Kerydin®, and Eucrisa®.

Why FDA Approval Is So Difficult for Biotech Startups

Before understanding how HPC helps, it is important to understand why biotech startups struggle with FDA approval in the first place.

Lack of In-House Regulatory Expertise

Most biotech startups are founded by scientists or entrepreneurs who are experts in their molecule but not in FDA regulations. Regulatory affairs is a specialized discipline that requires years of experience navigating FDA guidance documents, submission formats, and agency expectations. Hiring a full-time regulatory team is expensive and often impractical for an early-stage company.

Complexity of the FDA Approval Pathways

The FDA offers multiple approval pathways depending on the nature of your drug. An Investigational New Drug (IND) application is required before any human clinical trials can begin. A New Drug Application (NDA) is needed for full market approval. An Abbreviated New Drug Application (ANDA) applies to generic drugs, while the NDA 505(b)(2) pathway offers a middle route for reformulations and new dosage forms.

Choosing the wrong FDA pathway, or pursuing the right pathway with an incomplete strategy, can cost your startup months of delay and millions of dollars in wasted development spend.

High Cost of Errors

Unlike large pharmaceutical companies that can absorb delays, most biotech startups operate on limited funding with investor timelines attached. A Complete Response Letter (CRL) from the FDA, a failed bioequivalence study, or a manufacturing deficiency found during a pre-approval inspection can exhaust cash reserves and erode investor confidence. In drug development, it is almost always cheaper to get it right the first time.

Manufacturing and CMC Challenges

One of the most frequently underestimated aspects of FDA approval is the Chemistry, Manufacturing, and Controls (CMC) section. Regulators expect a deep scientific understanding of your manufacturing process, quality controls, stability data, and analytical methods. For a startup without GMP manufacturing experience, building a compliant CMC package from scratch is a major challenge.

How HPC Supports Biotech Startups at Every Stage

HPC takes a comprehensive, end-to-end approach to pharmaceutical consulting, providing guidance, documentation, and execution support from the earliest stages of development through to approval and commercialization.

1. IND Strategy and Filing Support

The IND application is the first major milestone in the clinical drug development process. HPC provides end-to-end IND filing support including:

Preclinical data review and gap analysis
Clinical trial protocol design and review
Pharmacology and toxicology section preparation
Manufacturing and CMC section development
FDA correspondence strategy and pre-IND meeting preparation

2. Regulatory Pathway Selection

HPC evaluates your molecule against all available pathways including:

IND to full NDA (standard development route)
NDA 505(b)(2) for reformulations, new delivery systems, or new combinations
ANDA for generic drug development and first-to-file strategies
Fast Track, Breakthrough Therapy, and Accelerated Approval for qualifying programs

HPC has helped multiple clients avoid the expensive mistake of pursuing a full NDA when a 505(b)(2) pathway was available, saving years of clinical development time and tens of millions of dollars.

3. Formulation Development

HPC’s formulation development services are built around the Quality by Design (QbD) framework, which is the FDA’s preferred approach to pharmaceutical development.

Formulation Expertise: HPC supports oral solid dosage forms including immediate release, controlled release, and modified release, as well as oral liquids, topical and transdermal formulations, parenteral and injectable formulations, and inhalation drug delivery systems.

4. Bioequivalence Study Design and Strategy

For companies pursuing ANDA or 505(b)(2) approvals, bioequivalence (BE) studies are often the most technically demanding part of the development program. A failed BE study can cost hundreds of thousands of dollars and delay approval by 12 to 18 months.

Most Common BE Study Failures: Poor study design, incorrect Reference Listed Drug (RLD) selection, failure to account for food effect, and underpowered sample sizes. All of these are preventable with the right expertise.

5. CMC Development and Documentation

The Chemistry, Manufacturing, and Controls (CMC) section is one of the most scrutinized parts of any NDA or ANDA submission. HPC provides comprehensive CMC consulting including:

Drug substance and drug product characterization
Manufacturing process development and optimization
Analytical method development and validation
Stability study design and data interpretation
CTD/eCTD Module 3 preparation
Technology transfer support from development to GMP manufacturing

6. Regulatory Affairs and Submission Management

HPC’s regulatory affairs services cover the full submission lifecycle including:

Pre-submission gap analysis and readiness assessment
CTD/eCTD dossier preparation and review
FDA meeting preparation for pre-IND, pre-NDA, and Type A/B/C meetings
Response to FDA deficiency letters and Complete Response Letters (CRLs)
Post-approval change management including CBE-0, CBE-30, and PAS supplements
International regulatory strategy for EMA and other global agencies

7. Compliance Audits and GMP Readiness

FDA approval is not a one-time event. It is an ongoing commitment to quality and compliance. HPC provides compliance audit services including:

Mock FDA inspections and audit readiness assessments
GMP gap analysis and remediation planning
Standard Operating Procedure (SOP) review and development
Quality Management System (QMS) evaluation
CAPA (Corrective and Preventive Action) program review

Compliance is not a burden. It is a business driver. HPC instills a culture of regulatory excellence in every organization it partners with.

8. Asset Assessment and Investor Engagement

For biotech startups navigating fundraising alongside drug development, HPC offers pharmaceutical asset assessment and investor engagement support including:

Independent technical and regulatory due diligence reports
Asset valuation support based on development stage and pathway
Investor presentation review and scientific narrative development
Partnering and licensing strategy consulting

HPC’s Track Record in Drug Development

HPC is not a theoretical consulting firm. Every service is grounded in real drug development experience and verifiable commercial outcomes.

Veltassa® (patiromer): Approved for hyperkalemia. Developed at Relypsa, acquired by Galenica for $1.52 billion.
Kerydin® (tavaborole): Approved for onychomycosis. Developed at Anacor Pharmaceuticals, acquired by Pfizer for $5.2 billion.
Eucrisa® (crisaborole): Approved for atopic dermatitis. Also developed at Anacor.
Intermezzo® (zolpidem tartrate): Developed at Transcept Pharmaceuticals for middle-of-the-night insomnia.

Who HPC Works With?

HPC works with a diverse range of clients across the pharmaceutical and biotech ecosystem including:

Early-stage biotech startups developing novel compounds or new formulations of existing drugs
Generic drug companies pursuing ANDA filings and first-to-file strategies
Venture capital and private equity firms conducting pharmaceutical due diligence
Academic spinouts translating research discoveries into clinical-stage programs
International pharma companies seeking to enter the US market through FDA approval
Investors and sovereign wealth funds evaluating pharmaceutical assets

Why Choose HPC Over Other Pharmaceutical Consultants?

Deep scientific expertise: HPC’s team includes PhDs in process chemistry, route synthesis analysis, and pharmaceutical sciences, not just regulatory generalists.
End-to-end support: HPC covers the full drug development lifecycle from formulation and CMC through regulatory submission and commercialization.
Proven commercialization experience: HPC’s leadership has direct experience with FDA-approved products, not just regulatory filings.
Personalized attention: As a boutique pharmaceutical consulting firm, HPC provides hands-on, senior-level engagement on every client program.
Global regulatory reach: HPC supports clients navigating FDA, EMA, and other international regulatory frameworks.
Strategic investor connectivity: HPC bridges the gap between science and investment, helping startups communicate their value to the financial community.

Get Started with HPC Today

Navigating FDA approval does not have to be overwhelming. With the right pharmaceutical consulting partner by your side, the regulatory pathway becomes a structured, manageable process with clear milestones and a defined route to market.

Contact Hayat Pharmaceuticals Consulting

Email: uhayat@hpc-us.com

Phone: +1-415-686-8822

Website: www.hpc-us.com

Address: 536 Shoreline Hwy., Mill Valley, CA 94941 USA

How Hayat Pharmaceuticals Consulting Helps Biotech Startups Navigate FDA Approval